Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated‐interferon and ribavirin therapy
暂无分享,去创建一个
F. Sanai | M. Elhefnawi | M. Al-Ahdal | A. Al-Qahtani | F. Alhamlan | A. Abdo | H. Al-Ashgar | A. Zaid | Nisreen Z. Khalaf
[1] F. Sanai,et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection , 2013, Hepatology International.
[2] Zhiliang Gao,et al. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype , 2012, Virology Journal.
[3] Zhiliang Gao,et al. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype , 2012, Virology Journal.
[4] M. Daw,et al. Hepatitis C Virus in Arab World: A State of Concern , 2012, TheScientificWorldJournal.
[5] Lin Deng,et al. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load , 2012, Journal of Gastroenterology.
[6] Masaya Sugiyama,et al. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[7] M. Satake,et al. Prevalence of Amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors , 2011, Journal of medical virology.
[8] M. Nei,et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.
[9] N. Maneekarn,et al. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy , 2011, Journal of viral hepatitis.
[10] Lin Deng,et al. Polymorphisms of Hepatitis C Virus Non-Structural Protein 5A and Core Protein and Clinical Outcome of Pegylated-Interferon/Ribavirin Combination Therapy , 2011, Intervirology.
[11] A. Tsubota,et al. Peginterferon and ribavirin treatment for hepatitis C virus infection. , 2011, World journal of gastroenterology.
[12] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[13] R. Chung,et al. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue? , 2009, The Journal of infectious diseases.
[14] M. Roggendorf,et al. Sequence diversity of hepatitis C virus: implications for immune control and therapy. , 2007, World journal of gastroenterology.
[15] Yoshiyuki Suzuki,et al. Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia , 2007, Intervirology.
[16] Milton W. Taylor,et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy , 2007, Journal of Virology.
[17] Yoshiyuki Suzuki,et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.
[18] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[19] Yoshiyuki Suzuki,et al. Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.
[20] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[21] G. Duverlie,et al. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. , 2003, Journal of virological methods.
[22] D. Stump,et al. Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. , 2002, RNA.
[23] K. Meyer,et al. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. , 2001, Virology.
[24] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[25] J. McLauchlan,et al. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes , 2000, Journal of viral hepatitis.
[26] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[27] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Korber,et al. Signature pattern analysis: a method for assessing viral sequence relatedness. , 1992, AIDS research and human retroviruses.
[29] J. Pawlotsky,et al. HCV Genome and Life Cycle , 2006 .
[30] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .
[31] T G Burland,et al. DNASTAR's Lasergene sequence analysis software. , 2000, Methods in molecular biology.
[32] T. A. Hall,et al. BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .
[33] A. Sangchan. Interferon Alfa-2b Alone or in Combination with Ribavin as Intial Treatment for Chronic Hepatitis C , 1998 .